Human embryonic stem cells (hESCs) can be maintained undifferentiated (pluripotent) or differentiated to basically all functional cell types, depending on the culture conditions used. Culture of hESCs in the presence of medium conditioned by mouse embryonic fibroblasts (MEFs) can be used to keep hESCs undifferentiated. This observation suggests that MEFs produce factors required for the pluripotency of hESCs. The data presented here show that fibroblast growth factor 2 (FGF2) treatment of MEFs is crucial for the production of these factors. To identify the potential factors that are expressed in the presence of FGF2 in MEFs, a global expression profile analysis using microarrays was performed. This analysis indicated that 17 secreted factors are downregulated in the absence of FGF2. These factors include several ligands for known signaling receptors, extracellular proteases and components of the extracellular matrix, that may all be involved in signaling events. Surprisingly, we found that selective blocking of extracellular signal-regulated kinase (ERK) signaling by the MAPK/ERK kinase (MEK) inhibitor U0126 affected the expression of only some of the FGF2-regulated genes, suggesting FGF2-induced pathways that are independent of ERK signaling. It has been shown recently that activation of Activin/Nodal signaling and inhibition of bone morphogenetic protein signaling are required for the maintenance of pluripotency. Accordingly, among the 17 FGF2-regulated genes we found inhibin βB that can lead to the assembly of Activin B and gremlin 1 that codes for an antagonist of bone morphogenetic proteins. This study identifies potentially important factors involved in the maintenance of pluripotency in hESCs and may allow the development of defined culture conditions without contaminating material from animal cells.

Keywords:
FGF2, Mouse embryonic fibroblasts, Human embryonic stem cells, Pluripotency
1.
Amit, M., M.K. Carpenter, M.S. Inokuma, C.P. Chiu, C.P. Harris, M.A. Waknitz, J. Itskovitz-Eldor, J.A. Thomson (2000) Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 227: 271–278.
2.
Amit, M., C. Shariki, V. Margulets, J. Itskovitz-Eldor (2004) Feeder layer- and serum-free culture of human embryonic stem cells. Biol Reprod 70: 837–845.
3.
Arman, E., R. Haffner-Krausz, Y. Chen, J.K. Heath, P. Lonai (1998) Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci USA 95: 5082–5087.
4.
Beattie, G.M., A.D. Lopez, N. Bucay, A. Hinton, M.T. Firpo, C.C. King, A. Hayek (2005) Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 23: 489–495.
5.
Besser, D. (2004) Expression of nodal, lefty-A, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3. J Biol Chem 279: 45076–45084.
6.
Chambers, I., D. Colby, M. Robertson, J. Nichols, S. Lee, S. Tweedie, A. Smith (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643–655.
7.
Eswarakumar, V.P., I. Lax, J. Schlessinger (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139–149.
8.
Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, R.A. Copeland, R.L. Magolda, P.A. Scherle, J.M. Trzaskos (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–18632.
9.
Greber, B., H. Lehrach, J. Adjaye (2007) Fibroblast growth factor 2 modulates transforming growth factor β signaling in mouse embryonic fibroblasts and human ESCs (hESCs) to support hESC self-renewal. Stem Cells 25: 455–464.
10.
Hay, D.C., L. Sutherland, J. Clark, T. Burdon (2004) Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 22: 225–235.
11.
Hollnagel, A., V. Oehlmann, J. Heymer, U. Ruther, A. Nordheim (1999) Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem 274: 19838–19845.
12.
Hsu, D.R., A.N. Economides, X. Wang, P.M. Eimon, R.M. Harland (1998) The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1: 673–683.
13.
Humphrey, R.K., G.M. Beattie, A.D. Lopez, N. Bucay, C.C. King, M.T. Firpo, S. Rose-John, A. Hayek (2004) Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells 22: 522–530.
14.
James, D., A.J. Levine, D. Besser, A. Hemmati-Brivanlou (2005) TGFβ/Activin/Nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132: 1273–1282.
15.
Levenstein, M.E., T.E. Ludwig, R.H. Xu, R.A. Llanas, K. VanDenHeuvel-Kramer, D. Manning, J.A. Thomson (2006) Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 24: 568–574.
16.
Mitsui, K., Y. Tokuzawa, H. Itoh, K. Segawa, M. Murakami, K. Takahashi, M. Maruyama, M. Maeda, S. Yamanaka (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631–642.
17.
Nichols, J., B. Zevnik, K. Anastassiadis, H. Niwa, D. Klewe-Nebenius, I. Chambers, H. Scholer, A. Smith (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95: 379–391.
18.
Puceat, M. (2007) TGFβ in the differentiation of embryonic stem cells. Cardiovasc Res 74: 256–261.
19.
Reubinoff, B.E., M.F. Pera, C.Y. Fong, A. Trounson, A. Bongso (2000) Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 18: 399–404.
20.
Sato, N., L. Meijer, L. Skaltsounis, P. Greengard, A.H. Brivanlou (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10: 55–63.
21.
Smith, A.G. (2001) Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 17: 435–462.
22.
Tanaka S., T. Kunath, A.K. Hadjantonakis, A. Nagy, J. Rossant (1998) Promotion of trophoblast stem cell proliferation by FGF4. Science 282: 2072–2075.
23.
Vallier, L., M. Alexander, R.A. Pedersen (2005) Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 118: 4495–4509.
24.
Xu, C., M.S. Inokuma, J. Denham, K. Golds, P. Kundu, J.D. Gold, M.K. Carpenter (2001) Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 19: 971–974.
25.
Xu, R.H., X. Chen, D.S. Li, R. Li, G.C. Addicks, C. Glennon, T.P. Zwaka, J.A. Thomson (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 20: 1261–1264.
26.
Xu, R.H., R.M. Peck, D.S. Li, X. Feng, T. Ludwig, J.A. Thomson (2005) Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods 2: 185–190.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.